Introduction
Pharmaceutical quality extends well beyond the assay of the active pharmaceutical ingredient. A drug substance or drug product may meet its assay requirement while still presenting regulatory considerations related to impurities arising from manufacturing processes, degradation, residual solvents, elemental contamination, raw materials, excipients, equipment, or packaging.
Consequently, impurity assessment has become an integral part of pharmaceutical development, Chemistry, Manufacturing and Controls (CMC), regulatory submissions, and post-approval lifecycle management.
The ICH Q3 series provides a fundamental regulatory framework for the assessment and control of several important categories of pharmaceutical impurities. The principal guidelines include:
- ICH Q3A(R2)– Impurities in New Drug Substances
- ICH Q3B(R2)– Impurities in New Drug Products
- ICH Q3C– Impurities: Guideline for Residual Solvents
- ICH Q3D– Guideline for Elemental Impurities
Although these guidelines address different impurity categories, they share a common regulatory objective: ensuring that impurities are appropriately understood, assessed, and controlled so that the quality and safety of pharmaceutical products are maintained.
Why Pharmaceutical Impurity Control Matters
Impurities can originate at virtually every stage of the pharmaceutical manufacturing lifecycle. Potential sources include:
- Starting materials and intermediates
- Reagents and catalysts
- Process-related reactions
- Manufacturing conditions
- Residual solvents
- Excipients
- Manufacturing equipment
- Drug-substance degradation
- Drug-product degradation
- Packaging materials
- Storage conditions
Therefore, the regulatory assessment should not be limited to determining whether an impurity is detectable.
A comprehensive assessment should address several fundamental questions:
- What is the impurity?
- Where does it originate?
- At what level is it present?
- What is the potential patient exposure?
- Does it require identification or qualification?
- How is it controlled?
- Will the control remain effective throughout the product lifecycle?
These questions form the foundation of an effective impurity control strategy.
Understanding the ICH Q3 Series
The ICH Q3 series should not be viewed as a single guideline. It consists of several complementary guidelines addressing different types of impurities. Understanding which guideline applies to a particular impurity is an important part of regulatory assessment.
ICH Q3A(R2): Impurities in New Drug Substances
ICH Q3A(R2) addresses impurities in new drug substances, particularly those arising from the synthesis and manufacturing process. Impurities may originate from:
- Starting materials
- Intermediates
- By-products
- Reagents
- Catalysts
- Degradation processes
- Other process-related sources
The guideline establishes principles for the reporting, identification, and qualification of impurities. A proper assessment therefore requires an understanding of the manufacturing process and the potential impurity profile generated by that process. The objective is not simply to detect impurities, but to establish that their levels are appropriately understood and controlled.
ICH Q3B(R2): Impurities in New Drug Products
While Q3A focuses on new drug substances, ICH Q3B(R2) addresses impurities in new drug products. Drug-product impurities may include degradation products and process-related impurities that arise during formulation and manufacturing. The impurity profile of a finished dosage form may differ from that of the API because additional chemical changes can occur during:
- Formulation
- Manufacturing
- Processing
- Packaging
- Storage
Potential degradation mechanisms include:
- Hydrolysis
- Oxidation
- Photolysis
- Thermal degradation
- Interaction with excipients
- Other formulation-related reactions
This makes impurity assessment closely linked with stability studies and shelf-life determination. A robust regulatory strategy should therefore evaluate impurity formation not only at product release but also throughout the proposed storage period.
ICH Q3C: Residual Solvents
Residual solvents are volatile organic chemicals used during pharmaceutical manufacturing that may remain in the drug substance, excipient, or drug product. ICH Q3C establishes a framework for their control based on their toxicological characteristics and acceptable patient exposure. The guideline categorizes solvents according to their potential risk and establishes appropriate limits based on permitted daily exposure principles. A risk-based assessment should consider:
- Which solvents are used?
- At what manufacturing stage are they used?
- Could they remain in the final material?
- What level is reasonably expected?
- What is the resulting patient exposure?
- Can the manufacturing process adequately remove or control them?
Residual solvent control may therefore involve a combination of:
- Process optimization
- Purification
- Drying
- In-process controls
- Supplier controls
- Analytical testing
The objective is not necessarily to test every possible solvent, but to establish a scientifically justified and appropriately controlled strategy.
ICH Q3D: Elemental Impurities
Elemental impurities can originate from several sources, including:
- Catalysts
- Starting materials
- Excipients
- Water
- Manufacturing equipment
- Container-closure systems
ICH Q3D introduced a risk-based approach for controlling elemental impurities in drug products. The assessment should consider the potential contribution from different sources and the resulting patient exposure. Depending on the product and manufacturing process, the assessment may consider:
- Drug substance contribution -Could the API manufacturing process introduce elemental impurities?
- Excipient contribution-Could one or more excipients contribute relevant elemental impurities?
- Manufacturing equipment -Could contact with equipment introduce elemental contamination?
- Water and utilities -Could process water or other materials contribute?
- Container-closure system -Could elements migrate from packaging into the drug product?
Based on the outcome of the risk assessment, an appropriate control strategy can be established, including analytical testing where scientifically justified.
Identification and Qualification: Two Different Regulatory Concepts
One of the most important principles in impurity assessment is understanding the difference between identification and qualification.
Identification addresses: What is the chemical identity of the impurity?
Depending on the impurity and its level, structural characterization may involve:
- Chromatographic comparison
- Mass spectrometry
- Reference standards
- NMR
- Other orthogonal analytical techniques
Qualification addresses: Is the impurity adequately supported from a safety perspective at the proposed level?
The assessment may consider:
- Existing safety information
- Literature data
- Structural information
- Toxicological assessment
- Patient exposure
- Appropriate qualification studies, where necessary
Therefore, identification and qualification should not be treated as interchangeable activities.
Reporting, Identification and Qualification Thresholds
The ICH Q3 framework uses threshold concepts to determine when impurities require additional regulatory consideration. These include:
- Reporting Threshold -The level above which an impurity should generally be reported.
- Identification Threshold -The level above which identification of an impurity may be required.
- Qualification Threshold -The level above which additional qualification may be necessary.
However, thresholds should not be interpreted in isolation. The assessment may also depend on:
- Maximum daily dose
- Route of administration
- Duration of treatment
- Chemical structure
- Existing safety information
- Toxicological considerations
- Nature of the impurity
A sound regulatory assessment therefore combines threshold evaluation with scientific and safety considerations.
Drug Substance and Drug Product Impurity Profiles Are Not Necessarily the Same
A common misconception is that the impurity profile of the API will automatically represent the impurity profile of the finished dosage form. In practice, the drug product may develop additional impurities during:
- Formulation
- Granulation
- Compression
- Coating
- Sterilization
- Packaging
- Storage
For example, an API that remains stable during its manufacturing process may undergo degradation after formulation with particular excipients or under certain storage conditions. This is why impurity assessment should consider the complete product lifecycle, rather than focusing exclusively on the API.
Impurities and Stability Studies
Impurity control is closely connected with pharmaceutical stability. During stability studies, relevant degradation products should be appropriately monitored to determine whether their levels increase during the proposed shelf life. Factors influencing impurity formation may include:
- Temperature
- Humidity
- Light
- Oxygen
- Packaging
- Formulation composition
- Manufacturing conditions
Stability data therefore provide important evidence supporting:
- Impurity specifications
- Degradation profiles
- Shelf-life
- Storage conditions
- Overall control strategy
This highlights an important regulatory principle: Impurity control is not limited to release testing; it must also demonstrate control throughout the proposed shelf life.
Analytical Methods and Impurity Control
Appropriate analytical procedures are essential for detecting, identifying, and monitoring impurities. Depending on the impurity category, techniques may include: HPLC, UPLC, GC, LC-MS, GC-MS, ICP-MS, ICP-OES, NMR and Other complementary analytical techniques
However, sophisticated instrumentation alone does not establish an adequate impurity control strategy. Analytical procedures should be appropriate for their intended purpose and adequately validated. Relevant analytical characteristics may include: Specificity, Accuracy, Precision, LOD, LOQ, Linearity, Range and Robustness
The analytical strategy should also be scientifically connected to the identified impurity risks.
Process Understanding Is the Foundation of Impurity Control
A robust impurity strategy should begin with process understanding. For a drug substance, this may involve evaluating:
Starting materials → Reaction steps → Intermediates → Reagents → Catalysts → Purification → Isolation → Final API
At each stage, potential impurity formation should be considered. For a drug product, the assessment may extend to: API + Excipients → Manufacturing Process → Packaging → Storage → Degradation
Understanding the source and mechanism of impurity formation enables manufacturers to determine where controls should be applied. In many cases, the most effective impurity control may be achieved through process design and prevention, rather than relying exclusively on finished-product testing.
A Risk-Based Approach to Elemental Impurities
One of the important aspects of ICH Q3D is its emphasis on risk assessment. A manufacturer should evaluate the potential contribution of elemental impurities from relevant sources and determine whether the resulting patient exposure is acceptable. This approach can help companies avoid unnecessary testing while ensuring that meaningful risks are adequately controlled. The overall process can be viewed as:
Identify potential sources → Assess contribution → Evaluate patient exposure → Determine controls → Confirm effectiveness where appropriate
This is an example of how modern pharmaceutical regulation increasingly emphasizes science- and risk-based decision-making.
Residual Solvent Control: Testing vs Process Control
Residual solvent management also demonstrates the importance of process understanding. Where a solvent is used during manufacturing, the manufacturer should understand:
- Its purpose
- Its point of use
- Its potential carryover
- Its removal capability
- Its expected residual level
- Its potential patient exposure
Depending on the risk, controls may be established through manufacturing processes, drying conditions, purification, specifications, or analytical testing. The regulatory objective is to demonstrate that residual solvents are appropriately controlled based on their risk.
Impurity Specifications Should Be Scientifically Justified
An impurity specification should not be viewed as an isolated numerical value. The proposed acceptance criterion should be supported by the overall understanding of:
- Manufacturing process
- Impurity profile
- Analytical capability
- Batch data
- Stability data
- Safety considerations
- Applicable regulatory requirements
A strong regulatory justification explains why the proposed limit is appropriate, rather than simply stating that the impurity meets the specification.
Common Regulatory Challenges Related to Impurities
Impurity-related regulatory questions may arise when:
- An impurity has not been adequately characterized
- Identification requirements are not appropriately addressed
- Qualification is insufficiently justified
- Analytical methods are not adequately demonstrated
- Degradation pathways are not sufficiently understood
- Stability data show an increasing impurity trend
- Proposed specifications lack adequate justification
- Elemental impurity risk assessments are incomplete
- Residual solvent controls are insufficiently justified
- The relationship between process controls and impurity levels is unclear
These gaps can result in additional regulatory questions and may delay regulatory review. A well-prepared CMC dossier should therefore present impurity information in a clear, logical, and scientifically connected manner.
Impurity Management During the Product Lifecycle
Impurity assessment does not end after marketing authorization. Changes throughout the product lifecycle may affect the impurity profile. Examples include:
- API manufacturer changes
- Manufacturing-site changes
- Route-of-synthesis changes
- Process modifications
- Scale-up
- Starting-material supplier changes
- Excipient supplier changes
- Formulation changes
- Packaging changes
- Shelf-life extensions
Before implementing a relevant change, the potential impact on the impurity profile should be assessed. Key questions include:
- Could the change introduce a new impurity?
- Could an existing impurity increase?
- Could a degradation pathway change?
- Could patient exposure change?
- Does the existing control strategy remain adequate?
This makes impurity assessment an important part of post-approval change management and lifecycle regulatory strategy.
ICH Q3 and Other Impurity Frameworks
The ICH Q3 series provides a fundamental framework for several major impurity categories, but it is not the only regulatory framework relevant to impurity assessment. Depending on the nature of the impurity, other guidelines and regulatory expectations may apply.
For example: ICH M7 addresses DNA-reactive and mutagenic impurities.
Regulatory authorities have also established specific expectations for nitrosamine impurities, including nitrosamine drug substance-related impurities. In addition, regulatory and scientific work continues to evolve in areas such as extractables and leachables. Therefore, a robust impurity assessment should first establish the nature, source, and potential risk of the impurity, followed by identification of the appropriate regulatory framework.
A Practical ICH Q3-Based Impurity Assessment Workflow
A practical regulatory approach can be structured into the following stages:
Step 1 — Understand the product and Review:
- API
- Dosage form
- Route of administration
- Maximum daily dose
- Formulation
- Manufacturing process
- Packaging
- Storage conditions
Step 2 — Identify potential impurity sources and Evaluate:
- Starting materials
- Process chemistry
- Solvents
- Catalysts
- Excipients
- Equipment
- Packaging
- Degradation pathways
Step 3 — Categorize the impurity - Determine whether the impurity falls within the scope of:
- Q3A
- Q3B
- Q3C
- Q3D
or whether another specialized impurity framework is more appropriate.
Step 4 — Assess the impurity and Consider:
- Identity
- Level
- Exposure
- Safety
- Reporting requirements
- Identification requirements
- Qualification requirements
Step 5 — Establish the control strategy and Potential controls include:
- Raw-material controls
- Supplier qualification
- Process controls
- Purification
- Specifications
- Analytical testing
- Packaging controls
- Stability monitoring
Step 6 — Maintain the strategy throughout the lifecycle
Reassess impurity risk following relevant changes to manufacturing, suppliers, formulation, packaging, site, or process.
What Should a Strong Regulatory Dossier Demonstrate?
A well-prepared regulatory submission should establish a clear connection between:
Manufacturing Process → Potential Sources of Impurities → Impurity Profile → Analytical Procedures → Identification and Qualification → Safety and Exposure Assessment → Specifications → Control Strategy → Stability → Lifecycle Management
This integrated approach enables regulatory reviewers to understand not only what the impurity limits are, but also why the proposed limits and controls are scientifically and regulatorily appropriate.
Conclusion
Pharmaceutical impurity management is a fundamental component of modern CMC and regulatory strategy. The ICH Q3 series provides a structured framework for assessing and controlling organic impurities, degradation products, residual solvents, and elemental impurities. However, effective impurity management goes beyond applying numerical thresholds. It requires an integrated understanding of:
- Where impurities originate.
- How they are formed or introduced.
- How they can affect patient exposure.
- How they can be detected and characterized.
- How they should be controlled.
- How the control strategy can be maintained throughout the product lifecycle.
For pharmaceutical companies and API manufacturers, this requires close coordination between Process Development, Analytical Development, Quality, Manufacturing, Toxicology, and Regulatory Affairs.
At RegOrbis Pharma, we support pharmaceutical and life-science organizations with regulatory strategy, CMC documentation, dossier preparation, DMF/CEP support, regulatory gap assessment, analytical and quality documentation, submissions, and post-approval lifecycle activities. Our objective is to connect scientific understanding with regulatory expectations and help clients develop robust, defensible, and commercially practical regulatory strategies.
How RegOrbis Pharma support
RegOrbis Pharma is a Regulatory Affairs & Life Sciences Consultancy supporting pharmaceutical, API, biotechnology, veterinary, nutraceutical, cosmetic, and healthcare organizations across global regulatory markets.
Our services include:
- Regulatory strategy and planning
- Global product registration
- CTD/eCTD/ACTD dossier preparation and compilation
- CMC and quality documentation
- DMF/ASMF/CEP support
- Medical and regulatory writing
- Lifecycle management
- Variations and renewals
- Regulatory intelligence
- Health authority response support
- Regulatory gap assessments
- Market-entry regulatory support
📧 Email: Info@regorbispharma.com
📱 Phone: +91 9967265308 / 9668430491
🌐 Website: www.regorbispharma.com